Sarah Sheikh

3.2k total citations · 1 hit paper
48 papers, 2.2k citations indexed

About

Sarah Sheikh is a scholar working on Pathology and Forensic Medicine, Oncology and Neurology. According to data from OpenAlex, Sarah Sheikh has authored 48 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pathology and Forensic Medicine, 9 papers in Oncology and 7 papers in Neurology. Recurrent topics in Sarah Sheikh's work include Multiple Sclerosis Research Studies (23 papers), Peripheral Neuropathies and Disorders (6 papers) and Polyomavirus and related diseases (6 papers). Sarah Sheikh is often cited by papers focused on Multiple Sclerosis Research Studies (23 papers), Peripheral Neuropathies and Disorders (6 papers) and Polyomavirus and related diseases (6 papers). Sarah Sheikh collaborates with scholars based in United States, Germany and United Kingdom. Sarah Sheikh's co-authors include Douglas L. Arnold, Katherine Dawson, Ralf Gold, Ludwig Kappos, Krzysztof Selmaj, Amit Bar‐Or, Minhua Yang, Gavin Giovannoni, Carlo Tornatore and Marianne T. Sweetser and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Neurology.

In The Last Decade

Sarah Sheikh

45 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

2012 1.3k citations Ralf Gold, Ludwig Kappos et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sarah Sheikh United States	18	1.3k	559	479	452	396	48	2.2k
Mariko Kita United States	16	1.1k 0.9×	420 0.8×	386 0.8×	415 0.9×	323 0.8×	31	1.9k
Kjetil Bjørnevik United States	22	1.3k 1.0×	627 1.1×	497 1.0×	471 1.0×	286 0.7×	62	2.7k
Alexey Boyко Russia	24	1.8k 1.4×	670 1.2×	544 1.1×	491 1.1×	500 1.3×	76	2.7k
Joël Oger Canada	31	1.4k 1.1×	1.1k 2.0×	398 0.8×	443 1.0×	484 1.2×	72	2.7k
Marianna Cortese United States	18	948 0.7×	378 0.7×	368 0.8×	357 0.8×	222 0.6×	44	2.1k
Øivind Torkildsen Norway	31	1.9k 1.4×	521 0.9×	714 1.5×	472 1.0×	322 0.8×	126	3.3k
Philippe Truffinet France	18	2.0k 1.5×	946 1.7×	290 0.6×	636 1.4×	622 1.6×	68	2.6k
Annette Oturai Denmark	27	1.2k 0.9×	271 0.5×	569 1.2×	450 1.0×	335 0.8×	71	2.3k
Carlo Avolio Italy	22	680 0.5×	286 0.5×	398 0.8×	306 0.7×	263 0.7×	75	1.8k
Douglas Jeffery United States	26	2.7k 2.0×	1.2k 2.2×	737 1.5×	768 1.7×	761 1.9×	84	3.7k

Countries citing papers authored by Sarah Sheikh

Since Specialization

Citations

This map shows the geographic impact of Sarah Sheikh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Sheikh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Sheikh more than expected).

Fields of papers citing papers by Sarah Sheikh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Sheikh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Sheikh. The network helps show where Sarah Sheikh may publish in the future.

Co-authorship network of co-authors of Sarah Sheikh

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Sheikh. A scholar is included among the top collaborators of Sarah Sheikh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Sheikh. Sarah Sheikh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sheikh, Sarah, et al.. (2025). Artificial intelligence in cardiovascular diagnostics: a systematic review and descriptive analysis of clinical applications and diagnostic performance. BMC Cardiovascular Disorders. 25(1). 849–849.

Sheikh, Sarah, et al.. (2021). Prognostic factors of unresectable hepatocellular carcinoma treated with yttrium-90 radioembolization: results from a large cohort over 13 years at a single center. Journal of Gastrointestinal Oncology. 12(4). 1718–1731. 4 indexed citations

Saida, Takahiko, Takashi Yamamura, Takayuki Kondo, et al.. (2019). A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries. BMC Neurology. 19(1). 5–5. 22 indexed citations

Calkwood, Jonathan, Timothy Vollmer, Robert J. Fox, et al.. (2015). Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered with Interferon Beta or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis. International Journal of MS Care. 18(3). 138–146. 7 indexed citations

Bar‐Or, Amit, Ralf Gold, Robert J. Fox, et al.. (2015). Five-Year Follow-up of Delayed-Release Dimethyl Fumarate in RRMS: Integrated Clinical Efficacy Data from the DEFINE, CONFIRM, and ENDORSE Studies (P7.234). Neurology. 84(14_supplement). 7 indexed citations

Kita, Mariko, Robert J. Fox, Ralf Gold, et al.. (2014). Effects of Delayed-Release Dimethyl Fumarate (DMF) on Health-Related Quality of Life in Patients With Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies. Clinical Therapeutics. 36(12). 1958–1971. 30 indexed citations

Arnold, Douglas L., Ralf Gold, Ludwig Kappos, et al.. (2014). Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. Journal of Neurology. 261(12). 2429–2437. 37 indexed citations

Viglietta, Vissia, Timothy R. Vollmer, Ray Zhang, et al.. (2014). Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered as Add-On Therapy to Beta Interferons or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients (I7-2.003). Neurology. 82(10_supplement). 1 indexed citations

Gold, Ralf, Amit Bar‐Or, Michael Hutchinson, et al.. (2014). 4-Year Follow-up of Delayed-Release Dimethyl Fumarate Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS): Integrated Clinical Efficacy Data From DEFINE, CONFIRM, and the ENDORSE Extension Study (P3.173). Neurology. 82(10_supplement). 1 indexed citations

10.

Kieseier, Bernd C., Thomas F. Scott, Scott D. Newsome, et al.. (2014). Peginterferon Beta-1a May Improve Recovery Following Relapses: Data from the Pivotal Phase 3 ADVANCE Study in Patients with Relapsing-Remitting Multiple Sclerosis (S4.003). Neurology. 82(10_supplement). 1 indexed citations

11.

Sheikh, Sarah, Ivan Nestorov, John O’Gorman, et al.. (2013). Tolerability and Pharmacokinetics of Delayed-Release Dimethyl Fumarate Administered With and Without Aspirin in Healthy Volunteers. Clinical Therapeutics. 35(10). 1582–1594.e9. 48 indexed citations

12.

Giovannoni, Gavin, Ralf Gold, Robert J. Fox, et al.. (2013). Relapses Requiring Intravenous Steroid Use and Multiple Sclerosis (MS)-Related Hospitalizations: An Integrated Analysis of the BG-12 (Dimethyl Fumarate) Phase 3 Studies (P07.121). Neurology. 80(7_supplement). 1 indexed citations

13.

Giovannoni, Gavin, Ralf Gold, Katherine Dawson, et al.. (2013). An integrated analysis of relapses requiring intravenous steroid use and multiple sclerosis (MS)-related hospitalizations from the BG-12 (dimethyl fumarate) phase 3 define and confirm studies. Value in Health. 16(3). A101–A102. 2 indexed citations

14.

Havrdová, Eva, Ralf Gold, Robert J. Fox, et al.. (2012). PND3 Relapses Requiring Intravenous Steroids and Multiple Sclerosis-Related Hospitalizations: Findings From the Phase 3 Define and Confirm Studies. Value in Health. 15(7). A546–A546. 2 indexed citations

15.

Greene, Sharon K., Melisa D. Rett, Eric Weintraub, et al.. (2012). Risk of Confirmed Guillain-Barre Syndrome Following Receipt of Monovalent Inactivated Influenza A (H1N1) and Seasonal Influenza Vaccines in the Vaccine Safety Datalink Project, 2009-2010. American Journal of Epidemiology. 175(11). 1100–1109. 70 indexed citations

16.

Gold, Ralf, Ludwig Kappos, Douglas L. Arnold, et al.. (2012). Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis. New England Journal of Medicine. 367(12). 1098–1107. 1318 indexed citations breakdown →

17.

Arnold, Douglas L., et al.. (2012). PND58 Effects of BG-12 on Quality of Life in Relapsing–Remitting Multiple Sclerosis: Findings From the Phase 3 Confirm Study. Value in Health. 15(7). A556–A556. 2 indexed citations

18.

Sheikh, Sarah, et al.. (2010). Meningitis associated with sphenoid sinus encephalocoele. Practical Neurology. 10(1). 43–44. 2 indexed citations

19.

Sheikh, Sarah, Ank E. Nijhawan, Nesli Basgoz, & Nagagopal Venna. (2008). Reversible Cogan’s syndrome in a patient with human immunodeficiency virus (HIV) infection. Journal of Clinical Neuroscience. 16(1). 154–156. 5 indexed citations

20.

Nakagawa, Kazuma, Sarah Sheikh, Matija Snuderl, Matthew P. Frosch, & Steven M. Greenberg. (2008). A new Thr49Pro transthyretin gene mutation associated with leptomeningeal amyloidosis. Journal of the Neurological Sciences. 272(1-2). 186–190. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact